VivoSeq
Other

Semaglutide

0

Pipeline Programs↗

16

Active Trials↗

6

Companies Involved↗

Semaglutide is an early-stage landscape with 0 programs across 6 companies. The most active players are Novo Nordisk, Actimed Therapeutics Ltd, Ascletis Pharma (China) Co., Limited.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

27/100

Mech. Concentration

N/A

Completion Rate

95/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

0 programs

PreclinicalA

Actimed Therapeutics Ltd

0 programs

PreclinicalA

Ascletis Pharma (China) Co., Limited

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalH

Halia Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

81

clinical trials

Completed57 · 70%
Recruiting9 · 11%
Not yet recruiting5 · 6%
Unknown status5 · 6%
Active, not recruiting2 · 2%
Withdrawn2 · 2%
Other1 · 1%

Clinical Trials

Trial Activity

81 trials

Genetics of the Acute Response to Oral Semaglutide
Recruiting·MMedical University of Bialystok·N/A·NCT05340868·1,000 enrolled
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Recruiting·AActimed Therapeutics Ltd·Phase 2·NCT07101939·120 enrolled
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Recruiting·UUniversity of California, Los Angeles·N/A·NCT05419726·20 enrolled
Semaglutide for Helping Opioid Recovery
Recruiting·—·Phase 2·NCT06639464·46 enrolled
Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients
Recruiting·SSt Andrew's Healthcare·Phase 4·NCT06754163·20 enrolled
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2/3·NCT06387199·26 enrolled
Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination
Recruiting·MMount Sinai Hospital, Canada·Phase 3·NCT07294950·98 enrolled
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment
Recruiting·UUniversity Hospital, Gentofte, Copenhagen·Phase 1/2·NCT07171723·24 enrolled
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 1·NCT07225816·75 enrolled
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
Active, not recruiting·Novo Nordisk logoNovo Nordisk·Phase 3·NCT05726227·210 enrolled
Semaglutide 2.4 mg in Patients With Poor Weight-loss
Active, not recruiting·UUniversity College, London·Phase 3·NCT05073835·70 enrolled
The Effect of Semaglutide on Bone Health
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 4·NCT07165158·150 enrolled
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
Not yet recruiting·LLMC Diabetes & Endocrinology Ltd.·N/A·NCT07424430·400 enrolled
A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects
Not yet recruiting·BBostal Drug Delivery Co., Ltd·Phase 1·NCT06422624·14 enrolled
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
Not yet recruiting·—·Phase 4·NCT07483801·112 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)